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Abstract: Little is known about the changes in gut resident flora during amebic colitis and amebic liver abscess
(ALA) caused by Entamoeba histolytica infection. Fecal samples from ALA patients, from healthy E. histolytica negative
and positive (asymptomatic) individuals, and from pre- and post-metronidazole–treated healthy volunteers and pus
samples from ALA patients were tested for the presence of various bacterial genera using 16S rRNA–based primers.
Statistically significant reduction in Lactobacillus due to E. histolytica infection was observed in asymptomatic individu-
als and ALA patients. On the other hand, reduction in Bacteroides, Bifidobacterium, and Clostridium in the same
samples was due to metronidazole treatment. Two anaerobic genera, viz. Bacteroides and Peptostreptococcus, were
detected in ALA pus samples, and this observation is unprecedented. In addition, PCR revealed metronidazole resis-
tance genes in fecal and pus samples of metronidazole-treated individuals. Re-examination of the ameba-bacterium
relationship in amebiasis is suggested.
INTRODUCTION
Amebiasis is a common worldwide disease in developing
countries, caused by infection with the protozoan parasite
Entamoeba histolytica. About 40,000 people are estimated to
die each year from amebic colitis and amebic liver abscess
(ALA).1 In most infected individuals, trophozoites in the in-
testine live as commensals without causing any noticeable
damage to the host. A small fraction of E. histolytica–infected
people present with clinical symptoms of colitis or extrain-
testinal invasion. The total number of infected individuals is
very high (up to 20% of the Indian population). In India ALA
is endemic.2 Most patients with an amebic liver abscess do not
have co-existent amebic colitis.3
In their natural environment, trophozoites of E. histolytica
live in the colonic region of the human intestine together with
resident microbial flora, which under normal conditions is
composed of a complex mixture of mostly anaerobic or mi-
croaerophilic bacteria.4 The predominant anaerobic species
in this flora belong to Bacteroides, Bifidobacterium, Eubacte-
rium, Clostridium, Peptococcus, Peptostreptococcus, and Ru-
minococcus, whereas facultative anaerobes, such as Escheri-
chia coli, Enterobacter, Enterococcus, Klebsiella, Lactobacil-
lus, and Proteus, are among the subdominant genera.5 The
composition of the individual’s flora can fluctuate in condi-
tions like acute diarrhea6 and antibiotic treatment. Although
the microbiota in healthy adults have been studied exten-
sively, little is known about the changes in flora that occur in
protozoan-associated gastrointestinal infection.
It has been suggested that the bacterial flora provides
anaerobic conditions or low redox potential beneficial for
amebic growth.7 Trophozoites of E. histolytica grown in as-
sociation with bacteria are active feeders that phagocytose
numerous bacteria.8 E. histolytica appears to be selective with
respect to association with different bacterial species, and
only those bacteria that possess the appropriate recognition
signals will become attached and ingested by the ameba. It
has been speculated that certain bacterial species of the gut
may trigger the virulent potential of the trophozoites while
others may have no effect or may even cause avirulence.9
Metronidazole is known to be clinically more effective against
ameba in tissue than lumenal ameba.10 This may be, in part,
due to anaerobic bacteria that co-exist with the amebic tro-
phozoites in vivo may bring about the reduction and elimina-
tion of metronidazole molecules needed for the killing of
amebic trophozoites.10 The incidence of metronidazole-
resistant anaerobic bacteria, especially some species of
Bacteroides, appears to be on the rise.11 A molecular study
demonstrated that the moderate resistance phenotype of
these clinical strains was in all cases associated with the pres-
ence of the 5-NI (nitroimidazole) resistance gene (nim).12
Systematic studies are lacking to provide a clinical correla-
tion between resident bacterial flora of the gut and the sever-
ity and spectrum of amebic disease. In the present study, we
have looked into the profile of predominant gut flora of
healthy individuals, asymptomatic E. histolytica carriers, and
amebic liver abscess patients. We have also addressed the
issue whether the changes observed in the gut flora may be
attributed to the administration of metronidazole or the pres-
ence of the parasite. We have also looked for the presence of
gut bacteria in the liver abscess aspirates. The prevalence of
the metronidazole-resistance gene (nim) was also scored in
these bacterial species. Our results indicate a significant loss
of some predominant gut bacteria in amebiasis patients and
the presence of some anaerobic species in amebic liver ab-
scess aspirates.
MATERIALS AND METHODS
Subjects. The present study included 35 patients with ame-
bic liver abscess admitted to the Gastroenterolgy Department
(All India Institute of Medical Sciences, New Delhi, India)
and 30 healthy individuals who were residing in a slum area of
New Delhi. Healthy individuals tested ranged in age from age
6 to 40 years and had not been on antibiotics for 3 months
prior to sample collection. They had no complaints of diar-
rhea, abdominal pain, or fever. Nineteen of 30 individuals
were negative for E. histolytica and were therefore considered
as “healthy, E. histolytica negative.” The remaining 11 (out of
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30) individuals were positive for E. histolytica, therefore con-
sidered as “healthy E. histolytica carriers” (asymptomatic).
Samples were also collected before and after metronidazole
treatment (300 mg twice per day; 3-day course) from a group
of 11 individuals: 8 healthy volunteers (residents of urban
area, Jawaharlal Nehru University Campus, India) and 3 pa-
tients suffering from irritable bowel syndrome (IBS) report-
ing to AIIMS.
Informed consent was obtained from patients and healthy
individuals prior to sample collection. Amebic liver abscess
patients were from different economic backgrounds and came
from different local areas in Delhi. Diagnosis of amebic liver
abscess was based on four or more of the following criteria: (i)
A space, occupying lesion in the liver diagnosed by ultraso-
nography and suggestive of abscess; (ii) clinical symptoms
(fever, abdominal pain), (iii) enlarged and/or tender liver,
usually without jaundice, (iv) in some cases diarrhea, and
bloody diarrhea in a few cases, and (v) positive amebic serol-
ogy. Of 35 patients, 33 were positive for amebic serology with
ELISA Kit containing IgG antibodies against E. histolytica
(R-Biopharm AG, Darmstadt, Germany). To avoid any sec-
ondary infection, amebic liver aspirates were collected only
from those patients who were being aspirated for the first
time. Out of 35 ALA patients, fecal samples were collected
from 19 ALA patients.
Most of the ALA patients were males (33/35). Most of
them had consumed metronidazole (mean duration of drug
intake, 6 days).
Fecal and ALA pus specimens. Fecal and pus samples were
collected from various categories of individuals, as listed in
the Tables 1 and 2. Aliquots of all fecal samples as well as pus
samples were preserved at –20°C till DNA isolation was done.
The aspiration procedure for ALA was carried out in a sterile
environment in the Intensive Care Unit by a clinician with the
required precautions.
Extraction of DNA from fecal or ALA pus specimens. Fe-
cal (0.2 g) and ALA pus samples (500 L) were used for
DNA extraction. DNA was extracted using the QIAamp
DNA stool mini kit (QIAGEN, Hilden, Germany) according
to the manufacturer’s instructions except that the suspension
was incubated in the kit’s stool lysis buffer at 95°C followed
by a 3-minute incubation with the InhibitEx tablets. The
DNA was eluted in 0.2 mL of AE buffer (supplied with the
QIAGEN kit).
PCR using genus-specific primers. Universal primer set;
S-D-Bact-0008-a-S-20 (5 AGA GTT TGA TCC TGG CTC
AG 3,13 which targets the domain Bacteria, and S-*-Univ-
1492-b-A-21 (5 ACG GCT ACC TTG TTA CGA CTT 3,14
which targets all living organisms, were used to amplify bac-
terial 16S rDNAs from the collected samples to ensure the
DNA quality. Later genus-specific primers were used to am-
plify the selected bacteria DNA from fecal and pus samples.
For all primer sets, 30-cycle PCR at different annealing
temperatures was performed in a Tech gene thermal cycler
(NuGEN Scientific, San Carlos, CA).15 Genus-specific primer
sets were designed from 16S rRNA sequences of the follow-
ing bacteria: Bifidobacterium (Bif), Clostridium (Clos), Ru-
minococcus (Rum), Campylobacter (Camp), Pseudomonas
aeruginosa (Pseudo), Lactobacillus (Lacb), and Peptococcus
(Pep). Specificity of these primers was checked by using tar-
get and non-targeted bacterial genomic DNA as described
previously.15 Primers for Bacteroides (Bacto) and Peptostrep-
tococcus productus (PSP) were obtained from the litera-
ture.16,17 All primers were commercially synthesized by Mi-
crosynth GmbH (Balgach, Switzerland).
Primer set used for the detection of Escherichia coli was
based on the mal B gene17 while for Staphylococcus aureus,
the primers mecA-1 and mecA-2 used were synthesized from
methicillin-resistant gene.18
Genomic DNA isolated from human blood (Genomic
DNA isolation kit, MBI Fermentas, St. Leon Rot, Germany)
was used as a template DNA for ensuring primers’ specificity.
PCR products derived from healthy individuals’ fecal DNA
were cloned and sequenced. These were used as controls in
subsequent PCR experiments.
Detection of E. histolytica-positive samples. For the PCR-
based detection of E. histolytica among all fecal and pus
samples, E. histolytica-specific UEE primers were used.19
Detection of nim genes. PCR assays were carried out using
the universal set of primers, Nim-3 and Nim-5, for all known
nim genes.20 These primers amplify a PCR product of 458 bp.
Amplification was done under conditions as previously de-
scribed21 using an annealing temperature of 52°C. Wild-type
strain Bacteroides fragilis (MTCC 1045) was used as a nega-
tive control.
Selected amplicons of nim genes (size  458 bp) obtained
for fecal and pus samples, were purified using a Qiagen Gel
Extraction kit and cloned into a pGEMT-Easy vector
TABLE 1
Prevalence of selected bacteria in fecal samples from healthy indi-
viduals and ALA patients
Bacteria
1
(n  19)
2
(n  11)
3
(n  19)
P value
1 vs 2 1 vs 3 2 vs 3
Bacto 12 9 3 – 0.0069 0.0013
Bif 16 8 4 – 0.0002 0.0086
PSP 12 10 14 – – –
Clos 14 8 4 – 0.0029 0.0086
Lacb 18 4 3 0.0011 0.0001 –
Rum 17 7 12 – – –
Camp 7 7 10 – – –
Pep 12 9 8 – – –
E. coli 10 2 12 – – 0.0259
Pseudo 6 10 7 0.0024 – 0.0067
* Only the significant P values are indicated; 1, healthy individuals, E. histolytica negative;
2, healthy individuals, E. histolytica positive; 3, stool samples from ALA patients.
TABLE 2
Effect of metronidazole* on the prevalence of selected bacteria in
fecal samples
Bacteria
4
(n  11)
5
(n  11)
P value
4 vs 5
Bacto 11 2 0.0002
Bif 11 4 0.0039
PSP 11 8 –
Clos 11 5 0.0124
Lacb 11 11 –
Rum 10 5 –
Camp 9 1 0.0019
Pep 11 6 0.0351
E. coli 2 8 0.0300
Pseudo 7 4 –
* In individuals not suffering from amebiasis (healthy volunteers and IBS patients).
† Only the significant P values are indicated; 4, before metronidazole treatment; 5, after
metronidazole treatment.
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(Promega Co., Madison, WI) as per the manufacturer’s in-
structions. Clones were further sequenced.
Analysis of sequenced data. Sequences obtained for repre-
sentative cloned amplicons from each category were analyzed
using the BLASTN program for a homology search within the
existing database for each genus.
Statistical analysis. One-way ANOVA and Fisher’s exact
tests were performed to check the statistical significance of
the data. Statistical significance was accepted at the level of
0.05, and probability values were calculated for two-tailed
possibilities.
RESULTS AND DISCUSSION
Changes in gastrointestinal flora. In their natural habitat,
the human large intestine, E. histolytica trophozoites co-exist
with hundreds of different bacterial species. The contribution
of these bacteria to the viability and virulence potential of E.
histolytica has been difficult to establish. Previous studies
have shown that trophozoites administered intracecally in
germ-free animals failed to establish themselves and produce
disease, whereas the introduction of single bacterial species
prior to administration of E. histolytica trophozoites in the
same animal resulted in active infection.22 E. histolytica is
known to efficiently phagocytose bacteria that may be a
source of nutrients for the growing trophozoites.9 In addition,
bacteria may provide the optimum conditions of pH and low
redox potential needed for E. histolytica survival. For a better
understanding of ameba-bacteria relationship, it is important
to determine what perturbations occur, if any, in the human
gut flora as a result of E. histolytica infection.
In the present study, two major aspects have been dealt
with: (i) changes in gastrointestinal flora as a result of E.
histolytica infections and (ii) bacterial co-infection in amebic
liver abscess.
Stool samples were analyzed from the following categories
of individuals: (1) healthy E. histolytica negative (N 19); (2)
healthy, asymptomatic, E. histolytica positive (N  11); and
(3) ALA patients (N  19). Pus samples were also analyzed
from ALA patients (N  35) for the presence of 11 promi-
nent, mostly anaerobic bacteria found in the human gut. Bac-
terial detection was done by PCR amplification of total DNA
from samples, using genus specific primers for 16S rRNA
gene. The specificity of detection was ascertained by sequenc-
ing the PCR-amplified bands and confirming their identity by
comparing with genus specific sequences available in the da-
tabase.
Figure 1 represents typical pattern for the PCR amplifica-
tion of various genera.
Percent incidence values were calculated from the PCR
results (Table 1). The significance of the PCR-based percent
incidence results was evaluated by statistical analysis. One-
way ANOVA test and two-tailed Fisher’s exact test indicated
a significant variation in fecal flora in the various categories
tested (Table 3). To confirm the results of PCR analysis from
stool and pus samples, randomly selected amplicons from
each primer set were cloned and sequenced. BLASTN results
revealed 94–100% identity with 16S rRNA sequences of the
corresponding bacterial species (from which the primer was
designed; data not shown). The sequences were submitted to
the database, and accession numbers were obtained (Table 4).
The high level of sequence identity showed that the assign-
ment of bacterial genera based on 16S rRNA was reliable.
Species names mentioned in Table 4 are based on the highest
score values in BLAST N results for the query sequence.
There was a statistically significant drop in the frequency of
four of the 11 bacterial genera, namely, Bacteroides (P 
0.0069), Bifidobacterium (P  0.0002), Lactobacillus (P 
0.0001), and Clostridium (P  0.0029) in fecal samples of
ALA patients (percent incidence 16–22%) when compared
with healthy, E. histolytica–negative controls. Of these, three
genera (Bacteroides, Bifidobacterium, and Clostridium) were
not reduced in healthy asymptomatic carriers (E. histolytica–
positive) compared with healthy E. histolytica–negative indi-
viduals (Table 1). However, Lactobacillus was reduced in E.
histolytica–asymptomatic carriers also (percent incidence 
36.3%; P  0.0011). Asymptomatic carriers also showed a
statistically significant decrease in the incidence of E. coli and
increase in Pseudomonas aeruginosa compared with the other
two categories of individuals. No significant changes were
observed for Peptostreptococcus productus, Ruminococcus,
Campylobacter, and Peptococcus among healthy controls and
ALA patients (Table 1).
Because ALA patients were on metronidazole treatment
for ethical reasons, and E. histolytica–asymptomatic carriers
had not taken metronidazole treatment, it was possible that,
the observed reduction in Bacteroides, Bifidobacterium, and
Clostridium in ALA patients alone was due to metronidazole
treatment while reduction in Lactobacillus seen in both ALA
patients and asymptomatic carriers was due to E. histolytica
infection.
TABLE 3
One-ANOVA test results*
Source of variation
Sum of
squares
Degrees of
freedom
Mean square
(S of S/df)
F ratio  Mean square
due to individual/
residual mean square
Due to individual 158.17 2 79 5.95
Residual 358 27 13.259
Total 516.17 29
H0, no variation in bacterial flora among different categories; H1, variation in bacterial
flora among different categories; Tab F(2,27)(0.05)  3.4; Cal F(2,27)(0.05)  5.95. Because Cal
F > Tab F, H0 is therefore rejected and H1 is accepted.
FIGURE 1. Typical PCR profile from fecal samples, using 16S
rRNA sequence–based primers from the indicated bacteria. Abbre-
viations are as in Materials and Methods. Expected amplicon sizes (in
bp) for each genus are as follows: Bacto, 948; Clos, 619; Nim, 458;
Camp, 969; Rum, 489; Lacb, 318; Pep, 539; Eco, 585; PSP, 267;
Pseudo, 1078; and Bif, 1300 (M  100-bp marker). Profiles shown
correspond to the healthy volunteers of Table 2.
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This was confirmed by directly testing the effect of metro-
nidazole on the gut flora of healthy volunteers (residents of
urban area) and IBS patients who were not suffering from
amebiasis. Bacterial flora in fecal samples of urban area resi-
dent healthy volunteers (taken before metronidazole treat-
ment) differed from the slum area resident healthy volun-
teers. This could be due to differences in their living condi-
tions and dietary habits.23 These individuals were given
metronidazole for a period of 3 days. None of these individu-
als was E. histolytica–positive, as tested by E. histolytica–
specific UEE primers.21
There was no change in the incidence of Lactobacillus in
these individuals as a result of metronidazole treatment, al-
though there was a marked drop in the incidence of Bifido-
bacterium, Bacteroides, and Clostridium. Metronidazole is
known to be very effective against obligate anaerobes, which
explains the drop in Bifidobacterium, Bacteroides, and
Clostridium.24 However, Lactobacillus, being facultative
anaerobe, is not significantly affected by this drug. Thus, our
results show that, of the 11 bacterial genera tested, at least
Lactobacillus is significantly reduced in individuals infected
with E. histolytica. Such a loss of anaerobic flora has been
reported under conditions of severe diarrhea25 and
Clostridium difficile–associated diarrhea.26
In keeping with the facts that metronidazole is effective
only against obligate anaerobic bacteria and that P. aerugi-
nosa is a strictly aerobic bacterium, no change was observed
in the incidence of P. aeruginosa in healthy volunteers and
IBS patients after metronidazole administration (Table 2).
Our observations regarding the low prevalence of E. coli in
the fecal samples of healthy adult individuals could be attrib-
uted to the fact that the level of this population may have
been below detectable limits before the drug treatment. This
could be due to the lower sensitivity of mal B gene–based
PCR primers used for the detection of E. coli. The 16S rRNA
gene could not be used for E. coli due to the lack of specific-
ity.27 As a result of drug-treatment overgrowth of aerobic
bacteria including E. coli may have occurred (Table 2), con-
comitant with the reduction in anaerobic bacteria as reported
earlier.28 This was also supported by a study carried out with
human fecal samples in which bifidobacteria were present in
higher number than E. coli.29
No significant change was observed in P. productus or Ru-
minococcus titers among the various categories of individuals
tested. Members of these genera are likely to be resistant both
to drug action as well as E. histolytica infection.
To our knowledge, an extensive investigation of bacterial
prevalence using sensitive DNA probes has not been carried
out with E. histolytica infected individuals. This needs to be
substantiated with more patients from a variety of geographical
locations. If a general pattern emerges, then a probiotic therapy
to replace the depleted bacterial species could be envisaged.
Bacteria in pus samples. DNA was extracted from ALA
pus samples and tested for the presence of various bacterial
genera as described for stool samples. No amplification was
observed with primers specific for aerobic bacteria (E. coli, S.
aureus, and P. aeruginosa).
A remarkable observation reported in this study is the
highly significant occurrence of Peptostreptococcus (25/35
ALA cases, 71.4% occurrence) and, less frequently, Bactero-
ides (5/35 ALA cases, 14.2% occurrence) in the pus samples
of ALA patients (Figure 2). Pus from these patients is gen-
erally considered to be sterile on the basis of culturing and
microscopy.9 Because our detection method was based on
PCR amplification, there could be a chance of primer cross-
reaction or bacterial contamination.
This was unlikely for the following reasons: (1) The primers
for Peptostreptococcus and Bacteroides did not have any
match with human DNA sequences and did not give any am-
plification with human blood DNA. (2) All precautions were
taken to collect the aspirated sample under sterile conditions;
these patients had never been aspirated before, hence there
was no possibility of prior infection for this reason. (3) Bac-
teria amplified by PCR (Peptostreptococcus and Bacteroides)
were both anaerobes, while primers from aerobic species (E.
coli, Pseudomonas aeruginosa, and methicillin-resistant S. au-
reus) did not give any amplification. Aerial contamination of
pus samples during aspiration would be more likely due to
TABLE 4
NCBI database accession numbers obtained for sequences of cloned
products
Bacteria Source Accession no.
Bacteroides species Healthy Eh −ve AM117604
B. vulgatus Healthy Eh −ve AM042696
B. species Healthy Eh +ve AM117577
B. species ALA stool sample AM117578
B. species ALA plus sample AM117579
Uncultured Clostridium species Healthy Eh −ve AM042697
C. species Healthy Eh +ve AM117582
C. species ALA stool sample AM117583
C. species ALA stool sample II AM117584
Uncultured Bifidobacterium
species Healthy Eh −ve AM042698
B. species Healthy Eh +ve AM117580
B. species ALA stool sample AM117581
Campylobacter coli Healthy Eh −ve AM042699
C. species Healthy Eh +ve AM117593
C. species ALA stool sample AM117594
Peptococcus species Healthy Eh −ve AM042700
RR-2005
Peptococcus species Healthy Eh +ve AM117585
P. species ALA stool sample AM117586
L. acidophilus Healthy Eh −ve AM042701
L. species Healthy Eh +ve AM117595
L. species ALA stool sample AM117596
Peptostreptococcus productus Healthy Eh −ve AM117587
P. productus Healthy Eh +ve AM117588
P. productus ALA stool sample AM117589
P. productus ALA pus sample 10 AM117590
P. productus ALA pus sample 17 AM117591
P. productus ALA pus sample 21 AM117592
Ruminococcus species Healthy Eh −ve AM117597
R. species Healthy Eh +ve AM117598
R. species ALA stool sample AM117599
E. coli Healthy Eh −ve AM117600
E. coli ALA stool sample AM117601
nim gene ALA stool sample AM117602
nim gene ALA pus sample AM117603
* Species were assigned on the basis of the highest score values in the BLAST results.
FIGURE 2. Amplicons for Bacto and PSP in selected ALA pus
samples (Table 4). Abbreviations are as in Materials and Methods.
Expected amplicon sizes (in bp) are as follows: Bacto, 948; and PSP,
267 (M  100-bp marker).
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aerobic species than anaerobes. (4) The PCR-amplified prod-
ucts obtained from Peptostreptococcus- and Bacteroides-
specific primers were sequenced. These showed 98% and
99% identity, respectively, with the known 16S rRNA se-
quences of these bacteria. Thus, it is not likely that the PCR
primers cross-reacted with contaminating aerobic bacteria in
the pus samples. From this we can conclude that ALA pus
samples do, indeed, contain DNA from Peptostreptococcus
and Bacteroides. Direct demonstration of bacteria by cultur-
ing needs to be made.
Several species of Peptostreptococcus and Bacteroides in-
cluding P. productus and B. fragilis are known to be involved
in causing abscesses and other septicemia-related infections in
humans. They are frequently associated with pyogenic liver
abscess.30 However, their involvement with ALA as sug-
gested here has not, so far, been reported. In a previous study,
superinfection of an amebic abscess with Salmonella enteridis
has been reported.31 However, in this case there was hemor-
rhage into the abscess due to physical trauma, which was
followed by secondary bacterial superinfection. Reports are
available about possible mechanisms of bacterial transloca-
tion to extraintestinal sites. These mechanisms, including in-
testinal bacterial overgrowth, are increased permeability of
mucosal barrier (leaky gut syndrome) and deficiencies in host
immune response.32 Whether these mechanisms continue to
operate in mixed infection of these anaerobic bacteria along
with the E. histolytica or whether bacteria passively gain entry
into the liver abscess caused by E. histolytica trophozoites
needs to be studied. It is important to know the extent of
involvement of bacteria in initiating or enhancing the severity
of ALA to effectively treat these patients.
Whether the bacteria detected by us were viable cannot be
assessed because PCR amplification alone was used. In an
attempt to cultivate bacteria from ALA pus samples from a
population of Bangladesh, only 19% samples were found to
be positive for a few aerobic gram- negative bacteria like E.
coli, Proteus, and Pseudomonas. However, presence of any
anaerobic bacteria was not reported.33 This could be due to
the difficulty in cultivating anaerobes. The very high inci-
dence of Peptostreptococcus reported here in pus samples (25
out of 35 ALA cases) is unprecedented. Bacteroides although
found in 5 out of 35 ALA cases, is unreported so far from pus
samples. Further confirmation of this data will require
anaerobic cultivation of viable bacteria from ALA pus
samples.
Presence of nim genes in ALA patients. In the last few
years, the occurrence of nim genes associated with metroni-
dazole resistance has been found to be widespread among
anaerobes, including Bacteroides34 and Peptostreptococcus.35
Many of these nim genes are plasmid encoded, while some are
also chromosomally located.36 Five nim genes, nimA to -E,
have been identified that confer reduced susceptibility to 5-ni-
troimidazole antibiotics (e.g., metronidazole) on species of
the B. fragilis group.34 The proposed resistance mechanism
conferred by the nim genes is that they encode a 5-nitroim-
idazole reductase.37 Four of the nim genes have been shown
to be associated with different mobile insertion sequence (IS)
elements flanked by inverted repeats. There is strong evi-
dence that these IS elements carry regulatory signals for ex-
pression of certain resistance genes, including the nim
genes.38
The presence of nim genes was determined in all fecal and
pus samples by PCR amplification with nim-specific prim-
ers.20 No amplicons were observed in healthy E. histolytica–
negative individuals and asymptomatic carriers, while ampli-
cons of the sizes expected for nim gene were present in both
pus and fecal samples of ALA patients (Table 5). Selected
clones of representative PCR products from both fecal and
pus samples of ALA patients were sequenced. Sequence
analysis using BLASTN revealed 99–100% identity with nim
E gene from B. fragilis (database entry) for amplicons from
both fecal and pus samples. Because ALA patients were re-
ceiving metronidazole, this result shows that nim genes may
be rapidly amplified in bacterial populations after antibiotic
challenge.
Among the healthy volunteers and IBS patients who were
given metronidazole treatment for a short duration (600 mg/
day, for 3 days), the nim gene amplicon was present in two of
the healthy volunteers before metronidazole treatment (per-
cent incidence, 18.8%); this frequency increased to 72.7%
after metronidazole treatment. Thus, metronidazole intake is
likely to result in the rapid appearance of metronidazole-
resistant bacteria in the Indian population.
The study presented here initiates discussion of the need to
rethink and reconsider the ameba-bacterium relationship in-
side the intestine and in extraintestinal tissues. The mecha-
nism by which anaerobic bacteria reach the amebic liver ab-
scess and their role, if any, in amebic pathogenesis need to be
explored using more experimental evidence.
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